MacroGenics Inc Shares Plummet 73% After Disappointing Vobra Duo Trial Results
Boston, MA – MacroGenics Inc, a biopharmaceutical company based in Maryland, faced a significant drop in its shares after releasing interim data from the TAMARACK Phase 2 study. The study focused on vobramitamab duocarmazine (vobra duo), a treatment targeting B7-H3, an antigen commonly found in various solid tumors. Conducted on patients with metastatic castration-resistant prostate … Read more